These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 26296840)

  • 1. Prognostic Significance of Muscle Attenuation in Pancreatic Cancer Patients Treated with Neoadjuvant Chemoradiotherapy.
    Akahori T; Sho M; Kinoshita S; Nagai M; Nishiwada S; Tanaka T; Tamamoto T; Ohbayashi C; Hasegawa M; Kichikawa K; Nakajima Y
    World J Surg; 2015 Dec; 39(12):2975-82. PubMed ID: 26296840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Borderline Resectable Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgical Resection.
    Kubo H; Murakami T; Matsuyama R; Yabushita Y; Tsuchiya N; Sawada Y; Homma Y; Kumamoto T; Endo I
    World J Surg; 2019 Dec; 43(12):3153-3160. PubMed ID: 31549202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma.
    Homma Y; Taniguchi K; Murakami T; Nakagawa K; Nakazawa M; Matsuyama R; Mori R; Takeda K; Ueda M; Ichikawa Y; Tanaka K; Endo I
    Ann Surg Oncol; 2014 Feb; 21(2):670-6. PubMed ID: 24310792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting.
    Fujii T; Satoi S; Yamada S; Murotani K; Yanagimoto H; Takami H; Yamamoto T; Kanda M; Yamaki S; Hirooka S; Kon M; Kodera Y
    J Gastroenterol; 2017 Jan; 52(1):81-93. PubMed ID: 27169844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal indication of neoadjuvant chemoradiotherapy for pancreatic cancer.
    Sho M; Akahori T; Tanaka T; Kinoshita S; Nagai M; Nishiwada S; Tamamoto T; Nishiofuku H; Ohbayashi C; Hasegawa M; Kichikawa K; Nakajima Y
    Langenbecks Arch Surg; 2015 May; 400(4):477-85. PubMed ID: 25929828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDG-PET predicts treatment efficacy and surgical outcome of pre-operative chemoradiation therapy for resectable and borderline resectable pancreatic cancer.
    Akita H; Takahashi H; Ohigashi H; Tomokuni A; Kobayashi S; Sugimura K; Miyoshi N; Moon JH; Yasui M; Omori T; Miyata H; Ohue M; Fujiwara Y; Yano M; Ishikawa O; Sakon M
    Eur J Surg Oncol; 2017 Jun; 43(6):1061-1067. PubMed ID: 28389044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery.
    Nagakawa Y; Sahara Y; Hosokawa Y; Murakami Y; Yamaue H; Satoi S; Unno M; Isaji S; Endo I; Sho M; Fujii T; Takishita C; Hijikata Y; Suzuki S; Kawachi S; Katsumata K; Ohta T; Nagakawa T; Tsuchida A
    Ann Surg Oncol; 2019 Jun; 26(6):1629-1636. PubMed ID: 30610555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer.
    Sho M; Akahori T; Tanaka T; Kinoshita S; Tamamoto T; Nomi T; Yamato I; Hokuto D; Yasuda S; Kawaguchi C; Nishiofuku H; Marugami N; Enomonoto Y; Kasai T; Hasegawa M; Kichikawa K; Nakajima Y
    J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):197-205. PubMed ID: 22766692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes and prognostic impact of inflammatory nutritional factors during neoadjuvant chemoradiotherapy for patients with resectable and borderline resectable pancreatic cancer.
    Oshima M; Okano K; Suto H; Ando Y; Kamada H; Masaki T; Takahashi S; Shibata T; Suzuki Y
    BMC Gastroenterol; 2020 Dec; 20(1):423. PubMed ID: 33317455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical analysis of cancer stem cell markers in pancreatic adenocarcinoma patients after neoadjuvant chemoradiotherapy.
    Mizukami T; Kamachi H; Mitsuhashi T; Tsuruga Y; Hatanaka Y; Kamiyama T; Matsuno Y; Taketomi A
    BMC Cancer; 2014 Sep; 14():687. PubMed ID: 25240521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Change Impact of Body Composition During Neoadjuvant Chemoradiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Pancreatectomy.
    Takaichi S; Tomimaru Y; Kobayashi S; Toya K; Sasaki K; Iwagami Y; Yamada D; Noda T; Takahashi H; Asaoka T; Tanemura M; Doki Y; Eguchi H
    Ann Surg Oncol; 2023 Apr; 30(4):2458-2468. PubMed ID: 36575288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The Efficacy of Neoadjuvant Chemoradiation Therapy for Borderline Resectable Pancreatic Cancer].
    Sano T; Takano K; Chiba N; Tomita K; Ozawa Y; Hikita K; Shimazu M; Kawachi S
    Gan To Kagaku Ryoho; 2015 Nov; 42(12):1488-90. PubMed ID: 26805072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemoradiotherapy followed by D2 gastrectomy in locally advanced gastric cancer.
    Kim MS; Lim JS; Hyung WJ; Lee YC; Rha SY; Keum KC; Koom WS
    World J Gastroenterol; 2015 Mar; 21(9):2711-8. PubMed ID: 25759540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postoperative pancreatic fistulas decrease the survival of pancreatic cancer patients treated with surgery after neoadjuvant chemoradiotherapy: A retrospective analysis.
    Uchida Y; Masui T; Nagai K; Anazawa T; Yoshimura M; Uza N; Takaori K; Mizowaki T; Uemoto S
    Surg Oncol; 2020 Dec; 35():527-532. PubMed ID: 33160278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Muscle wasting and survival following pre-operative chemoradiotherapy for locally advanced rectal carcinoma.
    Levolger S; van Vledder MG; Alberda WJ; Verhoef C; de Bruin RWF; IJzermans JNM; Burger JW
    Clin Nutr; 2018 Oct; 37(5):1728-1735. PubMed ID: 28756039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Neoadjuvant Chemotherapy Using S-1 for Pancreatic Cancer - Mid-Term Results].
    Homma Y; Honda G; Sakamoto K; Kurata M; Honjo M; Hirata Y; Shinya S
    Gan To Kagaku Ryoho; 2016 Oct; 43(10):1166-1170. PubMed ID: 27760934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant chemoradiotherapy of pancreatic cancer induces a favorable immunogenic tumor microenvironment associated with increased major histocompatibility complex class I-related chain A/B expression.
    Murakami T; Homma Y; Matsuyama R; Mori R; Miyake K; Tanaka Y; Den K; Nagashima Y; Nakazawa M; Hiroshima Y; Ueda M; Tanaka K; Hoffman RM; Bouvet M; Endo I
    J Surg Oncol; 2017 Sep; 116(3):416-426. PubMed ID: 28608409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does the computed tomography perfusion imaging improve the diagnostic accuracy in the response evaluation of esophageal carcinoma to the neoadjuvant chemoradiotherapy? Preliminary study.
    Djuric-Stefanovic A; Saranovic D; Micev M; Stankovic V; Plesinac-Karapandzic V; Pesko P; Stojakov D; Sabljak P; Bjelovic M
    J BUON; 2014; 19(1):237-44. PubMed ID: 24659670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inverse Probability of Treatment Weighting Analysis of Upfront Surgery Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Pancreatic Adenocarcinoma with Arterial Abutment.
    Fujii T; Yamada S; Murotani K; Kanda M; Sugimoto H; Nakao A; Kodera Y
    Medicine (Baltimore); 2015 Sep; 94(39):e1647. PubMed ID: 26426657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A gene expression signature for predicting response to neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma.
    Nishiwada S; Sho M; Cui Y; Yamamura K; Akahori T; Nakagawa K; Nagai M; Nakamura K; Takagi T; Ikeda N; Li W; Baba H; Goel A
    Int J Cancer; 2021 Feb; 148(3):769-779. PubMed ID: 32895958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.